title: Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
abstract: Lupus nephritis (LN) is the major determinant of outcome in pediatric systemic lupus erythematosus (pSLE), and its treatment remains a challenge. The aim of this study was to report the experience of our center in treating with rituximab (RTX) SLE patients with severe LN. Four pSLE patients with biopsy-proven LN, who are refractory to conventional immunosuppressive treatment, received four doses of 375-500 mg/m(2) RTX, 2-3 weeks apart. All patients were concurrently receiving corticosteroids (CSs) and mycophenolate mofetil. Patients' clinical and laboratory findings were recorded at RTX initiation, after each infusion and at 3.4 ± 2.1 month intervals thereafter. pSLE activity was assessed using the European Consensus Lupus Activity Measurement (ECLAM), while LN activity using 24-hour urine protein excretion and serum cystatin C. Patients were followed up for 6-21 months (median: 16 months). Full Β-cell depletion was noticed 2-4 weeks after RTX initiation and lasted 4-7 months. All patients achieved complete LN remission 3.5 months (range: 2-4) after RTX initiation, which was retained in 3 patients through the follow-up period. One patient relapsed 15 months after RTX initiation and received one additional RTX dose. ECLAM scores and CSs doses were markedly reduced in all patients, while complement levels were increased. No side effects or infections were observed. In conclusion, RTX is an alternative, safe and efficient treatment for refractory LN.
authors.affiliation: First Department of Pediatrics, Aristotle University of Thessaloniki, Thessaloniki, Greece. mtrachan@auth.gr
authors.forename: Maria
authors.initials: M
authors.lastname: Trachana
authors.forename: Artemis
authors.initials: A
authors.lastname: Koutsonikoli
authors.forename: Evagelia
authors.initials: E
authors.lastname: Farmaki
authors.forename: Nikoleta
authors.initials: N
authors.lastname: Printza
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Tzimouli
authors.forename: Fotios
authors.initials: F
authors.lastname: Papachristou
mesh_terms: D000293:Adolescent; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab
references.citation: J Pediatr. 2006 May;148(5):623-627
references.pmid: 16737873
references.citation: Autoimmun Rev. 2009 Feb;8(4):343-8
references.pmid: 19036350
references.citation: Nephrol Dial Transplant. 2009 Dec;24(12):3717-23
references.pmid: 19617257
references.citation: Arthritis Rheum. 2007 Apr 15;57(3):538-42
references.pmid: 17394185
references.citation: Arthritis Rheum. 1997 Sep;40(9):1725
references.pmid: 9324032
references.citation: Arthritis Rheum. 2007 Sep;56(9):3044-56
references.pmid: 17763423
references.citation: Best Pract Res Clin Rheumatol. 2009 Aug;23(4):563-74
references.pmid: 19591785
references.citation: Lupus. 2003;12(10):798-800
references.pmid: 14596432
references.citation: Lupus. 2010 Feb;19(2):213-9
references.pmid: 19965944
references.citation: Arthritis Rheum. 2009 Apr 15;61(4):482-7
references.pmid: 19333973
references.citation: J Rheumatol. 2011 Apr;38(4):633-41
references.pmid: 21159836
references.citation: Lupus. 2009 Aug;18(9):767-76
references.pmid: 19578100
references.citation: Arthritis Res Ther. 2006;8(3):R83
references.pmid: 16677395
references.citation: Nephrol Dial Transplant. 2009 Jul;24(7):2157-60
references.pmid: 19179411
references.citation: Clin Biochem. 2007 Mar;40(5-6):383-91
references.pmid: 17316593
references.citation: Arthritis Rheum. 2003 Jun 15;49(3):335-41
references.pmid: 12794788
references.citation: J Am Soc Nephrol. 2004 Feb;15(2):241-50
references.pmid: 14747370
references.citation: Arch Dis Child. 2008 May;93(5):401-6
references.pmid: 18039744
references.citation: Arthritis Rheum. 2005 Oct;52(10):3168-74
references.pmid: 16200620
references.citation: Arthritis Rheum. 2010 Aug;62(8):2458-66
references.pmid: 20506527
references.citation: Pediatr Nephrol. 2006 Apr;21(4):598-9
references.pmid: 16508774
references.citation: Expert Rev Clin Immunol. 2009 Jul;5(4):391-403
references.pmid: 20477036
references.citation: Arthritis Rheum. 2009 Sep 15;61(9):1281-2
references.pmid: 19714598
references.citation: Acta Paediatr. 2010 Jul;99(7):967-74
references.pmid: 20222881
references.citation: Clin Immunol. 2008 Jun;127(3):280-5
references.pmid: 18337174